GSK Redundancies 2026: Around 350 R&D Roles
Last updated: 1 September 2026
GSK has announced a round of UK research and development job cuts in 2026, alongside plans to close its long-standing Stevenage site and move most roles to a new Cambridge centre.
What has been publicly announced
GSK announced on 3 February 2026 that it was cutting around 350 research and development jobs across the US and UK as part of an R&D overhaul, including around 50 roles at its Stevenage, Hertfordshire site.
Source: The Comet, 3 February 2026.
In a further stage of the same R&D restructuring, GSK announced on 28 July 2026 that it would close its Stevenage research and development site, which employs around 1,800 staff, moving around 1,000 scientists to a new Cambridge Biomedical Campus centre in a phased relocation by 2029, as part of a wider £1.9bn annual cost-savings programme.
Source: Bdaily, 28 July 2026.
This page reports only what has been publicly announced, with a source and date against every claim. It does not suggest GSK has acted unlawfully, and nothing here should be read as a comment on the merits of any individual case.
Personally affected by GSK?
Where are you in the process?
Choose the closest option. We will take you to the relevant questions, with no obligation to proceed.
Your rights in a redundancy at GSK
GSK's situation does not change the statutory rules that apply to any UK redundancy: our redundancy consultation guide covers collective consultation and protective awards, and redundancy vs settlement agreement covers how a settlement agreement interacts with a redundancy exit, including the independent legal advice you are entitled to have your employer pay for.
What you are entitled to regardless of what GSK offers
Whatever GSK ultimately offers, if you have at least 2 years' continuous service with GSK you are entitled by law to statutory redundancy pay (a week's pay per full year of service, more for older employees, less for younger ones, capped at £751 a week and 20 years' service for 2026/27, a maximum of £22,530), your notice period or pay in lieu, accrued but untaken holiday pay, and a genuine consultation process, regardless of anything GSK negotiates on top.
The most recent public reporting on this GSK programme is dated 28 July 2026; nothing since has changed the statutory floor above, which you can work out for your own age, service and pay with our redundancy pay calculator (see also being made redundant: what happens next).
We have not identified a publicly sourced enhanced redundancy scheme specific to GSK. If your offer states an enhanced multiple, your adviser checks it as part of the settlement agreement review below.
What to check before signing
Before you sign anything, work out what you are owed regardless of any negotiation, and what is genuinely on the table. These guides cover the detail:
Sources
Disclaimer
This page provides general information about a publicly reported workforce situation. It is not legal, tax or benefits advice, and your position depends on your own facts. We are not connected to GSK; its name is used only to identify the publicly reported situation. Sources and dates are given for every factual claim above. For advice on your own circumstances, speak to a qualified adviser. Law as at 1 September 2026.